WhiteLab Genomics Series B: €23.2M

Oct 5, 2026Public sources — Collected from public sources, not yet cross-checked.

WhiteLab Genomics raised €23.2 million (about $26.14 million) in a series b round led by AVP, announced Oct. 5.

Facts

Company: WhiteLab Genomics
Amount: €23.2 million (about $26.14 million)
Currency: EUR
Stage: Series B
Announced: Oct 5, 2026
Instrument: Equity
FX rate: 1 EUR = 1.1269 USD on Oct 5, 2026

Investors

Led by: AVP
Participants: Yaday Health Blast Club Omnes Capital Debiopharm Innovation Fund

Use of funds

Funding the expansion of in vivo validation work beyond AAVs to non-viral delivery technologies, strengthening the Boston hub, growing West Coast presence, and exploring opportunities in Japan and South Korea.

As stated by the company.

Sources

1.Paris-based WhiteLab Genomics raises €23.2 million to accelerate AI-driven genomic medicine development — EU-Startups, Oct 6, 2026

Public sources — Collected from public sources, not yet cross-checked.Last verified Oct 15, 2026